Kite Pharma, Inc.
6 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
Recorded under 2 name spellings.
0
Ending by 2030
May 2036
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 2 fees due Jan 25 to 30, 2027 · next Jan 25
- 1 fee due Apr 24, 2027The maintenance fee for Chimeric Antigen and T Cell Receptors and Methods of Use (US 11,793,834) comes due Apr 24, 2027. Unpaid by Oct 25, 2027, it lapses early.
- 1 fee due May 21, 2027The maintenance fee for T cell receptor antigen binding molecules and methods of use thereof (US 11,820,823) comes due May 21, 2027. Unpaid by Nov 22, 2027, it lapses early.
- 2 fees due Jun 5 to 10, 2027 · next Jun 5
- 1 fee due Sep 30, 2027The maintenance fee for Chimeric antigen and T cell receptors and methods of use (US 10,603,380) comes due Sep 30, 2027. Unpaid by Mar 31, 2028, it lapses early.
- 1 fee due Oct 21, 2027The maintenance fee for Antigen binding molecules specific for an anti-CD19 scFv (US 10,626,187) comes due Oct 21, 2027. Unpaid by Apr 21, 2028, it lapses early.
Recent changes
- 4 of the patents on this record were granted since Aug 16, 2026
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 12,458,654 | Methods of Conditioning Patients for T Cell Therapy In force · High confidence | In force | High confidence | |
| US 12,559,718 | Diagnostic Methods for T Cell Therapy In force · High confidence | In force | High confidence | |
| US 10,365,939 | Method and Apparatus for Providing Operating System Based on Lightweight Hypervisor In force · High confidence | In force | High confidence | |
| US 10,603,380 | Chimeric antigen and T cell receptors and methods of use In force · From the USPTO record | In force | From the USPTO record | |
| US 10,689,450 | Bcma Binding Molecules and Methods of Use Thereof In force · High confidence | In force | High confidence | |
| US 10,501,775 | Antigen binding molecules and methods of use thereof In force · From the USPTO record | In force | From the USPTO record | |
| US 11,505,613 | Bcma Binding Molecules and Methods of Use Thereof In force · High confidence | In force | High confidence | |
| US 11,384,155 | Antigen binding molecules specific for an anti-CD19 scFv In force · From the USPTO record | In force | From the USPTO record | |
| US 10,626,187 | Antigen binding molecules specific for an anti-CD19 scFv In force · From the USPTO record | In force | From the USPTO record | |
| US 12,202,909 | Antigen binding molecules specific for an anti-CD19 scFV In force · From the USPTO record | In force | From the USPTO record |
Also on record, not counted in the 50: 6 patents in force now held by others. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
45 pending · 14 abandoned · 17 no status recorded